Preclinical findings indicate potential synergistic effects between cisplatin and CDK4/6 inhibitors in several cancers, such as esophageal squamous cell carcinoma, ovarian cancer, bladder cancer, and breast cancer. Here, CDK4 is linked to urinary bladder carcinoma.